Who We Are?

CIRO Pharma Private Limited plant at Biotech Park Phase III is aimed at manufacturing of Anti-Cancer Drugs for regulatory markets like U.S.A, U.K, Europe, Canada and South America.

We are coming up with a state of the art world class exclusive anti-cancer drugs manufacturing plant at Hyderabad.

The products majorly include monoclonal anti bodies, cancer therapeutics in the form of oral solid dosages, capsules and injunctions. Nutrition and dietary supplements for cancer patients in the form of soft gel capsules is also part of our manufacturing portfolio.

At CIRO Pharma R&D center we have proposed to eliminate contra indications like renal failures in cancer patients. Mal nutrition and uneven metabolism will also be addressed by our R&D department.

The expansion plans of the plant will house a manufacturing facility for sexual hormones for both male and female along with birth control pills.

The R&D for Hormones will address contra indications by way of nano technology. The management has proposal to market the following formulations for cancer therapy.

Chairman’s Message


As you all are aware that I am venturing into Pharmaceutical industry from my parent business of Mining Equipment manufacturing, I put forward the progress of my quarter year progress before you all for your suggestions and blessings.

The thought of venturing into Pharmaceutical industry is out of my urge to work closely with human health. As an entrepreneur, I have lot of options like real estate, trading etc., but this very idea of saving human lives through an enterprise struck me to take this division. As I result the CIRO Pharma Pvt Ltd., has been floated with my family members and industry experts as directors on board.

The Government of Telangana, through TSIIC under the benevolent leadership of Shri KT Rama Rao garu as Minister and Shri Venkata Narasimha Reddy garu as Managing Director are doing extremely great job in industry promotion at Hyderabad. They have allotted us 6 Acres of Land at Plot No 28, Biotech Park Phase 3, Karakapatla, for which we remain grateful always.

The land has huge rocky terrain everywhere and that seemed to be a difficult job for us to plane it. But out of my experience at Dandumalkapur, TIF park, I have succeeded in clearing the boulders in a record time of 60 days.

We have built up of 3 floors of R&D block and production block construction is in progress. We have plans to complete the construction by November 2022.

The equipment program me is also in currency. We have initiated the same with world leaders like GEA, CVC, BOSCHE, ACG, Sterile, EMA etc.

From boulders to buildings, we are here today. With a all your wishes hope we will commence production by July 2023.


  • To become a highly respectful, knowledge based domestic and global enterprise in manufacturing of Oncology products (Lyophilized, tablets, capsules and Liquid injections (vials & ampoules), Soft Gel Capsules both therapeutic use and nutritional supplementary nutraceutical’s, in Phase -1.
  • In Phase -2, company plans to manufacture Human Vaccines, Hormonal products (Tablets & Capsules), Biosimilars (Therapeutic proteins, Monoclonal antibodies) & In-vitro Diagnostics and also poultry vaccines (Live and killed bacterial and viral vaccines).
  • To comply with developed countries regulations like USFDA, PICS, EMEA, Health Canada, TGA Australia, MCC South Africa, UK-MHRA, WHO-PQ ,PMDA Japan and ANVISA Brazil.
  • Stand for ‘Leadership Position of quality products and aim to be a Contract Pharma Manufacturing player in improving the quality of Human life to comply with National regulatory requirements.
  • Vision sets out the framework and objectives for the future, and directs everyone in the organization towards achieving the set goals.
  • Aim is to be a growing company, driven by experiencing the true sense of self- respect with a high level of integrity.
  • Creative translation of 'Innovative Ideas' with a vision of 'Powerful Future' is our ambition in respect of quality drugs.


  • To provide quality assured, effective, safe, available, affordable and accessible health solutions to people for a healthier and prosperous society with improved socio-economic footprint.
  • To provide chemically advanced, innovative and low-cost appliances resulting in reduced deceases, hospitalization of patients and high returns as savings on medical bills.

Administrative Team

DR. K. Govinda Reddy
Chairman & Managing Director
B. Tech, MBA, Ph.D
Y. Madhusudhan Reddy
Director & CEO
M.Com, MBA (IIM-K), LLB, (PhD)
K. Harshitha Reddy
MS (Sweden), MBA, (PhD)
DR. K. Someshwar
M. Pharm PhD

Technical Team

Strategy & Planning

Formulations Industry

Formulation studies involve developing a preparation of the drug which is both stable and acceptable to the patient. For orally administered drugs, this usually involves incorporating the drug into a tablet or a capsule. It is important to make the distinction that a tablet contains a variety of other potentially inert substances apart from the drug itself, and studies have to be carried out to ensure that the encapsulated drug is compatible with these other substances in a way that does not cause harm, whether direct or indirect. Pre-formulation involves the characterization of a drug's physical, chemical, and mechanical properties to choose what other ingredients (excipients) should be used in the preparation. In dealing with protein pre-formulation, the important aspect is to understand the solution behavior of a given protein under a variety of stress conditions such as freeze/thaw, temperature, shear stress among others to identify mechanisms of degradation. Formulation studies then consider such factors as particle size, polymorphism, pH, and solubility, as all of these can influence bioavailability and hence the activity of a drug. The drug must be combined with inactive ingredients by a method that ensures that the quantity of drug present is consistent in each dosage unit e.g., each tablet. The dosage should have a uniform appearance, with an acceptable taste, tablet hardness, and capsule disintegration. It is unlikely that formulation studies will be complete by the time clinical trials commence. This means that simple preparations are developed initially for use in phase I clinical trials. These typically consist of hand-filled capsules containing a small amount of the drug and diluents.

Proof of the long-term stability of these formulations is not required, as they will be used (tested) in a matter of days. Consideration has to be given to what is known as "drug loading" - the ratio of the active drug to the total contents of the dose. Pharmaceutical formulation development links the discovery of a new drug substance to the successful development of a commercial drug product. Formulation development scientists must determine the most appropriate route to achieving effective drug delivery based on patient need, then optimize the formulation’s characteristics based on a knowledge of the drug product’s bioavailability and processing requirements.

This is a difficult challenge. Only 10% of new drug products in preclinical formulation development successfully reach the market. With the costs of pharmaceutical development rising, and pressure to release drug pipeline value also increasing, innovator drug development companies are applying significant effort to determining how to speed effective formulation selection. Developing a complete understanding of the form and structure of the drug substance and drug product is seen as a key enabler.

Similar challenges exist for generic pharmaceutical companies, where successful development of complex drug formulations remains difficult. There is a significant untapped market for new complex generics. Guided

Physicochemical Analysis

Malvern Panalytical’s physicochemical techniques are routinely applied to address these formulation challenges. Our solutions are used to characterize physicochemical properties and better understand the drug substance and drug product form, to aid excipient selection and understand excipient function within formulations, and to assess how storage or processing may affect drug product performance. Our expertise enables the right data to be delivered, providing insights which unlock formulation development success.

Drug product formulation

Development of a successful pharmaceutical formulation requires the combination of the active pharmaceutical ingredient (API) with inactive excipients. Excipients may be simple bulking agents, designed to aid control of the dose content uniformity. Increasingly, though, some excipients have a functional role in controlling drug release or ensuring the drug reaches the desired site of action. Here, compatibility between the selected excipient and the drug substance is critical in ensuring the correct dose is delivered within the required therapeutic window. Physicochemical analysis can aid excipient selection, enable the stability of the drug substance and drug product to be assessed, and also ensure the critical material attributes (CMAs) relating to formulation performance are identified as part of the design space definition applied for downstream manufacturing controls.

Complex formulations

The increasingly complex requirements for achieving reproducible drug delivery are a common challenge for formulation development scientists. Many new active pharmaceutical ingredients (APIs) are poorly soluble, meaning that traditional oral solid dose delivery is no longer relevant. Formulation complexity is therefore increasing, either to enable increased bioavailability for oral administration, or to enable local delivery so that the drug concentration at the site of action meets therapeutic requirements.

Novel drug delivery systems, based on liposomes or other nanoparticle delivery systems, are being utilized more frequently to improve drug targeting. Malvern Analytica’s range of complementary analysis techniques enable formulation developers to understand API and excipient formulation and stability. This aids the optimization of complex formulations, saving time in selecting an effective candidate formulation.

Complex generics

The challenges of developing complex formulations also extend to the development of generic drug products. Regulators around the world have recognized the impact of a lack of successful complex generic product introductions on healthcare costs.